Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0008991046
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG002NCK5M5
ADMA

ADMA Biologics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ADMA Biologics Inc
ISIN
US0008991046
TICKER
ADMA
MIC
XNAS
REUTERS
ADMA.OQ
BLOOMBERG
ADMA US
Wed, 30.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 30, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Tue, 29.10.2024       ADMA Biologics

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:...
Tue, 29.10.2024       ADMA Biologics

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET...
Mon, 28.10.2024       ADMA Biologics

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:...
Mon, 28.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 28, 2024) -   Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting ht...
Fri, 25.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 25, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Fri, 25.10.2024       ADMA Biologics

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Thu, 24.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 24, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Tue, 22.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 22, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Sun, 20.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 20, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Silent Ad
Fri, 18.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 18, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://ww...
Thu, 17.10.2024       ADMA Biologics

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Wed, 16.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 16, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Tue, 15.10.2024       ADMA Biologics

Boston, Massachusetts--(Newsfile Corp. - October 15, 2024) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https...
Mon, 14.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 14, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Sat, 12.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 12, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://w...
Thu, 10.10.2024       ADMA Biologics

New York, New York--(Newsfile Corp. - October 10, 2024) -  Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting htt...
Tue, 17.09.2024       ADMA Biologics

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Mon...
Tue, 10.09.2024       ADMA Biologics

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in...
Thu, 01.08.2024       ADMA Biologics

Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET...
Silent Ad